Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6326-6338

  Kondo, Shunsuke ^a   Iwata, Satoshi ^b   Yamada, Taketo ^d   Inoue, Yusuke ^g   Ichihara, Hiromi ^c   Kichikawa, Yoshiko ^b   Katayose, Tomoki ^b   Souta Kuribara, Akiko ^b   Yamazaki, Hiroto ^b   Hosono, Osamu ^b   Kawasaki, Hiroshi ^b   Tanaka, Hirotoshi ^b   Hayashi, Yuichiro ^d   Sakamoto, Michiie ^d   Kamiya, Kazunori ^e   Dang, Nam H ^h   Morimoto, Chikao ^f  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b University of Tokyo   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Tokyo Medical and Dental University   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f JUNTENDO UNIVERSITY   (Japan)

^g KITASATO UNIVERSITY HOSPITAL   (Japan)

^h UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BETA1 INTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; PROTEIN NEDD9; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL SPREADING; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE SILENCING; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CRK-ASSOCIATED SUBSTRATE PROTEIN; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTEGRINS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; QUINAZOLINES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84869217941     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2162     Document Type: Article

References (52)

1. Boyle P, Levin B. International Agency for Research on Cancer, World Health Organization. World cancer report 2008. Lyon, France; Geneva, Switzerland: International Agency for Research on Cancer; Distributed by WHO Press; 2008.
2. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97. (Pubitemid 41007845)
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25.
4. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S-40S. (Pubitemid 32880077)
5. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, et al. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer 2001;3:27-32. (Pubitemid 32904309)
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
8. Morello V, Cabodi S, Sigismund S, Camacho-Leal MP, Repetto D, Volante M, et al. β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 2011;30:4087-96.
9. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009;69:1383-91.
10. Walker JL, Assoian RK. Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev 2005;24:383-93. (Pubitemid 41569978)
11. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
12. ffrench-Constant C, Colognato H. Integrins: versatile integrators of extracellular signals. Trends Cell Biol 2004;14:678-86.
13. Nojima Y, Rothstein DM, Sugita K, Schlossman SF, Morimoto C. Ligation of VLA-4 on T cells stimulates tyrosine phosphorylation of a 105-kD protein. J Exp Med 1992;175:1045-53.
14. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes. J Exp Med 1996;184:1365-75. (Pubitemid 26354693)
15. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J 1994;13:3748-56. (Pubitemid 24275020)
16. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun 1992;185:1155-61.
17. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol 1996;16:3327-37.
18. O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA. A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9. Cancer Res 2007;67:8975-9. (Pubitemid 47535876)
19. Ohashi Y, Tachibana K, Kamiguchi K, Fujita H, Morimoto C. T cell receptor-mediated tyrosine phosphorylation of Cas-L, a 105-kDa Crk-associated substrate-related protein, and its association of Crk and C3G. J Biol Chem 1998;273:6446-51. (Pubitemid 28144739)
20. Manie SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, et al. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem 1997;272:4230-6. (Pubitemid 27078492)
21. Tachibana K, Urano T, Fujita H, Ohashi Y, Kamiguchi K, Iwata S, et al. Tyrosine phosphorylation of Crk-associated substrates by focal adhesion kinase. A putative mechanism for the integrin-mediated tyrosine phosphorylation of Crk-associated substrates. J Biol Chem 1997;272:29083-90. (Pubitemid 27498196)
22. van Seventer GA, Salmen HJ, Law SF, O'Neill GM, Mullen MM, Franz AM, et al. Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway. Eur J Immunol 2001;31:1417-27. (Pubitemid 32454689)
23. Ohashi Y, Iwata S, Kamiguchi K, Morimoto C. Tyrosine phosphorylation of Crk-associated substrate lymphocyte-type is a critical element in TCR- and beta 1 integrin-induced T lymphocyte migration. J Immunol 1999;163:3727-34. (Pubitemid 29450895)
24. Iwata S, Souta-Kuribara A, Yamakawa A, Sasaki T, Shimizu T, Hosono O, et al. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene 2005;24:1262-71. (Pubitemid 40313927)
25. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007;448:807-10. (Pubitemid 47266337)
26. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 2006;125:1269-81. (Pubitemid 43949521)
27. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24. (Pubitemid 41112921)
28. Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res 2010;70:4054-63.
29. Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, et al. An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest 2011;121:880-92.
30. Li Y, Bavarva JH, Wang Z, Guo J, Qian C, Thibodeau SN, et al. HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression. Oncogene 2011;30:2633-43.
31. Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Research 2010;70:824-31.
32. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int J Cancer 2005;116:36-44. (Pubitemid 40834296)
33. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
34. Inoue Y, Tojo A, Sekine R, Soda Y, Kobayashi S, Nomura A, et al. In vitro validation of bioluminescent monitoring of disease progression and therapeutic response in leukaemia model animals. Eur J Nucl Med Mol Imaging 2006;33:557-65.
35. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002;100:3175-82. (Pubitemid 35217065)
36. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene 2006;25:1721-32.
37. de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J Biol Chem 1997;272:32649-55. (Pubitemid 28011956)
38. Lee JW, Juliano RL. The alpha5beta1 integrin selectively enhances epidermal growth factor signaling to the phosphatidylinositol-3-kinase/Akt pathway in intestinal epithelial cells. Biochim Biophys Acta 2002;1542:23-31.
39. Ding Q, Stewart J Jr, Olman MA, Klobe MR, Gladson CL. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem 2003;278:39882-91. (Pubitemid 37248551)
40. Moro L, Dolce L, Cabodi S, Bergatto E, Boeri Erba E, Smeriglio M, et al. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. J Biol Chem 2002;277:9405-14. (Pubitemid 34953026)
41. Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, et al. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res 2009;7:923-32.
42. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249-56.
43. Sakai K, Arao T, Shimoyama T, Murofushi K, Sekijima M, Kaji N, et al. Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor. FASEB J 2006;20:311-3. (Pubitemid 46671154)
44. Law SF, O'Neill GM, Fashena SJ, Einarson MB, Golemis EA. The docking protein HEF1 is an apoptotic mediator at focal adhesion sites. Mol Cell Biol 2000;20:5184-95. (Pubitemid 30431571)
45. Seo S, Asai T, Saito T, Suzuki T, Morishita Y, Nakamoto T, et al. Crk-associated substrate lymphocyte type is required for lymphocyte trafficking and marginal zone B cell maintenance. J Immunol 2005;175:3492-501. (Pubitemid 41292006)
46. Brinkman A, van der Flier S, Kok EM, Dorssers LC. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;92:112-20. (Pubitemid 30089867)
47. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48. (Pubitemid 37433395)
48. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I, et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 2006;66:4672-80.
49. Briknarova K, Nasertorabi F, Havert ML, Eggleston E, Hoyt DW, Li C, et al. The serine-rich domain from Crk-associated substrate (p130cas) is a four-helix bundle. J Biol Chem 2005;280:21908-14. (Pubitemid 40827842)
50. Lucas JT Jr, Salimath BP, Slomiany MG, Rosenzweig SA. Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent. Oncogene 2010;29:4449-59.
51. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, Koontz J, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. (Pubitemid 44200650)
52. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42. (Pubitemid 46631407)